Market Movers (8-K)
See all →OID
Avenue Therapeutics secured an exclusive worldwide license from Duke University for ATX-04 to treat Pompe disease, leveraging existing clinical data.
Capital raise
OID
Avenue Therapeutics, Inc. announced that its stockholders approved the election of six directors and ratified KPMG LLP as its independent auditor for 2025 at the annual meeting.
OID
Avenue Therapeutics, Inc. has announced December 30, 2025, as the date for its annual meeting of stockholders and established deadlines for shareholder proposals and director nominations.
OID
Avenue Therapeutics divests its majority-owned subsidiary Baergic Bio to Axsome Therapeutics, securing an upfront payment and potential future milestone and royalty payments for its epilepsy drug candidate.
OID
Avenue Therapeutics and AnnJi Pharmaceutical have terminated their license agreement, with Avenue transferring rights to AJ201 back to AnnJi and receiving potential milestone payments and royalties.
OID
Avenue Therapeutics, Inc. has been notified by Nasdaq that its common stock will be delisted due to non-compliance with minimum stockholders' equity requirements.
Worse than expected
Quarterly Earnings (10-Q)
See all →OID
Avenue Therapeutics reported a net loss of $0.7 million for Q1 2026, a significant improvement from the prior year, as the company advances its ATX-04 and IV tramadol programs.
Capital raise
Worse than expected
OID
Avenue Therapeutics reports significant net loss reduction in Q3 2025, driven by asset sales and cost cuts, amidst Nasdaq delisting and going concern doubts.
Worse than expected
Delay expected
Capital raise
OID
Avenue Therapeutics reports Q2 2025 results, including revenue from AnnJi license termination and a net income attributable to Avenue.
Worse than expected
Capital raise
OID
Avenue Therapeutics reported its Q1 2025 financial results, detailing a net loss reduction, Nasdaq delisting, and the termination of the AnnJi License Agreement.
Worse than expected
Capital raise
OID
Avenue Therapeutics reported a net loss of $3.1 million for the third quarter of 2024, while advancing its clinical programs for AJ201, IV tramadol, and BAER-101.
Worse than expected
Capital raise
OID
Avenue Therapeutics reported its Q2 2024 financial results, noting a net loss but also highlighting advancements in its clinical programs and recent capital raising activities.
Worse than expected
Capital raise
Annual Reports (10-K)
OID
Avenue Therapeutics reports its 10-K filing for FY 2024, highlighting a delisting notice from Nasdaq and an ongoing dispute with AnnJi over the AJ201 license agreement.
Capital raise
Worse than expected
OID
10-K: Avenue Therapeutics Details Capital Structure, Voting Rights, and Warrant Information in SEC Filing
Avenue Therapeutics' 10-K filing provides a comprehensive overview of its capital stock, including common stock, preferred stock, and various warrants, along with their associated rights and terms.
Capital raise
Insider Trading (Form 4)
See all →OID
Fortress Biotech, a 10% owner and director, increased its beneficial ownership in Avenue Therapeutics by 111,209 shares of common stock as an annual dividend.
OID
Fortress Biotech, a 10% owner of Avenue Therapeutics, acquired 33,724 shares of common stock as an equity fee following Avenue Therapeutics' receipt of proceeds from warrant exercises.
OID
Avenue Therapeutics director Neil Herskowitz sold 23 shares of common stock at $2.97 per share on December 2, 2024.
OID
Director Jay D. Kranzler of Avenue Therapeutics, Inc. (ATXI) sold 61 shares of common stock at $2.24 per share on November 5, 2024.
OID
Director Jay D Kranzler increased his holdings in Avenue Therapeutics through open market purchases of common stock.
OID
Director Lindsay A. Rosenwald acquired 30,000 employee stock options in Avenue Therapeutics, Inc. on September 23, 2024.
Proxy Statements (Def-14A)
OID
Avenue Therapeutics, Inc. announced its virtual Annual Meeting of Stockholders for December 30, 2025, to elect directors and ratify KPMG LLP as its independent auditor.
Capital raise
OID
Avenue Therapeutics has filed a definitive proxy statement with the Securities and Exchange Commission.
OID
Avenue Therapeutics is holding its annual stockholder meeting on June 24, 2024, to vote on the election of directors, ratification of auditors, and an amendment to the company's incentive plan.
OID
Avenue Therapeutics' board of directors has approved a reverse stock split, ranging from 30-for-1 to 75-for-1, to increase its stock price and maintain its Nasdaq listing.
Schedule 13D - Activist Investments
OID
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.4% following an annual equity grant.
OID
SCHEDULE 13D/A: Fortress Biotech Solidifies Control and Equity Stake in Avenue Therapeutics with Amended 13D Filing
Fortress Biotech, Inc. has filed an Amendment No. 7 to its Schedule 13D, updating its beneficial ownership in Avenue Therapeutics, Inc. to 10.3% and detailing its continued voting majority through Class A preferred stock and ongoing equity grants.
Capital raise
OID
SCHEDULE 13D/A: Fortress Biotech Increases Stake in Avenue Therapeutics, Maintains Voting Majority Through Preferred Stock
Fortress Biotech, Inc. has increased its beneficial ownership in Avenue Therapeutics, Inc. to 13.8% through equity grants, solidifying its control via Class A preferred stock.
Capital raise
Schedule 13G - Passive Investments
OID
SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 4.99% Passive Stake in Avenue Therapeutics, Inc.
Armistice Capital, LLC and Steven Boyd have filed an amended Schedule 13G, reporting a 4.99% beneficial ownership stake in Avenue Therapeutics, Inc. as of December 31, 2024.
OID
Ikarian Capital, LLC and Neil Shahrestani have jointly disclosed a passive 6.8% beneficial ownership stake in Avenue Therapeutics, Inc., holding 140,000 shares of common stock.